Skip to Content
Merck
CN

SML4154

Pemafibrate

new

≥98% (HPLC)

Synonym(s):

(2R)-2-[3-[[2-Benzoxazolyl[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid, (R)-2-[3-[[Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid, K 13675, K 877, K-13675, K-877, K13675, K877, (R)-K13675, (R)-K-13675, (R)-K13675

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C28H30N2O6
CAS Number:
Molecular Weight:
490.55
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

SMILES string

COC(C=C1)=CC=C1OCCCN(CC2=CC(O[C@H](CC)C(O)=O)=CC=C2)C3=NC4=C(O3)C=CC=C4

General description

Pemafibrate is an orally active, highly potent and selective peroxisome proliferator-activated receptor alpha (PPARα) agonist (hPPAR EC50 = 1 nM/α, 1.10 μM/γ, 1,58 μM/δ by cell-based reporter assays using respective transfectants). When administered in vivo Pemafibrate is>100-fold more effective than fenofibrate in lowering triglyceride (TG) innormal rats (1 mg/kg p.o.) and in increasing HDL-cholesterol (HDL-C) in humanapoA-I (h-apoA-I) transgenic mice (3 mg/kg p.o.). Compared to other fibrates, pemafibrate′s distinct Y-shaped structure aids in stronger PPAR-α activation, better lipid binding, greater potency, and adaptability tostructural changes caused by binding of coactivators. Pemafibrate shows anti-inflammatory activities like lowering the levels of interleukin-6, tumor necrosis factor-α, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1 (VCAM-1), macrophage marker F4/80). It also exhibits antiatherogenic effects by lowering the levels of certain factors such as plasma triglycerides(TG), TG-rich lipoproteins, and apolipoprotein C-III (apoC-III), and increases lipoprotein lipase (LPL) activity and high-density lipoprotein (HDL) levels. Pemafibrate promotes fibroblast growth factor 21 and contributes to the reduction of insulin resistance.

Application

Pemafibrate may be used in research studies tostudy its effects on lipid metabolism, inflammation, and cardiovascular health.

Biochem/physiol Actions

Orally active, highly potent and selective peroxisome proliferator-activated receptor alpha (PPARα) agonist with >100-fold in vivo efficacy than fenofibrate.
Pemafibrate is an orally active, highly potent and selective peroxisome proliferator-activated receptor alpha (PPARα) agonist (hPPAR EC50 = 1 nM/α, 1.10 μM/γ, 1,58 μM/δ by cell-based reporter assays using respective transfectants). When administered in vivo Pemafibrate is >100-fold more effective than fenofibrate in lowering triglyceride (TG) in normal rats (1 mg/kg p.o.) and in increasing HDL-cholesterol (HDL-C) in human apoA-I (h-apoA-I) transgenic mice (3 mg/kg p.o.).

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service